Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

The EMA has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites.

Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of IGV-001, in ndGBM individuals.